FY2025 Earnings Forecast for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at HC Wainwright decreased their FY2025 EPS estimates for Celldex Therapeutics in a research note issued on Tuesday, November 11th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($3.67) for the year, down from their prior estimate of ($3.34). HC Wainwright currently has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2025 earnings at ($1.03) EPS.

A number of other equities research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Mizuho initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target for the company. Wells Fargo & Company decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, August 20th. Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Finally, Barclays cut their price objective on Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.80.

Celldex Therapeutics Price Performance

CLDX stock traded down $0.02 during trading on Thursday, hitting $24.23. 133,419 shares of the stock traded hands, compared to its average volume of 1,015,047. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $29.05. The firm’s 50 day moving average is $25.49 and its two-hundred day moving average is $22.82. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -8.07 and a beta of 1.36.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new position in Celldex Therapeutics in the 3rd quarter worth $26,000. Nisa Investment Advisors LLC grew its holdings in shares of Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics in the third quarter valued at about $42,000. Russell Investments Group Ltd. raised its position in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Celldex Therapeutics during the third quarter valued at $63,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.